Flucytosine and cryptococcosis:: Which in vitro test is the best predictor of outcome?

被引:15
作者
Viviani, MA [1 ]
Esposto, MC [1 ]
Cogliati, M [1 ]
Tortorano, AM [1 ]
机构
[1] Univ Milan, IRCCS, Osped Maggiore, Ist Igiene & Med Prevent, I-20122 Milan, Italy
关键词
flucytosine; Cryptococcus neoformans; cryptococcosis; in vitro susceptibility; outcome of treatment;
D O I
10.1179/joc.2003.15.2.124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The combination of flucytosine and amphotericin B is first choice treatment for active cryptococcosis. Because of innate or acquired resistance of Cryptococcus neoformans to flucytosine, in vitro testing is mandatory. Yeast nitrogen base (YNB) at pH 7.0 is the recommended medium for the broth microdilution test (NCCLS M27-A) and for the E-test. In order to verify if minimum inhibitory concentrations (MICs) were able to predict treatment outcome, the susceptibility of 24 isolates from 21 patients treated with flucytosine alone or in combination was tested by the broth microdilution, agar dilution and E-test using YNB either at pH 7.0 or at pH 5.4. Only those MICs obtained on YNB pH 5.4 proved to correlate with treatment outcome. The present study suggests that in vitro susceptibility to flucytosine of C. neoformans isolates should be evaluated on YNB pH 5.4 and the test should be standardized accordingly.
引用
收藏
页码:124 / 128
页数:5
相关论文
共 11 条
[1]   Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998 [J].
Brandt, ME ;
Pfaller, MA ;
Hajjeh, RA ;
Hamill, RJ ;
Pappas, PG ;
Reingold, AL ;
Rimland, D ;
Warnock, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3065-3069
[2]   SUSCEPTIBILITY TESTING OF CRYPTOCOCCUS-NEOFORMANS - A MICRODILUTION TECHNIQUE [J].
GHANNOUM, MA ;
IBRAHIM, AS ;
FU, Y ;
SHAFIQ, MC ;
EDWARDS, JE ;
CRIDDLE, RS .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (11) :2881-2886
[3]  
National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
[4]   OXYGEN AS LIMITING NUTRIENT FOR GROWTH OF CRYPTOCOCCUS-NEOFORMANS [J].
ODDS, FC ;
DEBACKER, T ;
DAMS, G ;
VRANCKX, L ;
WOESTENBORGHS, F .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (04) :995-997
[5]   Antifungal susceptibility testing: Practical aspects and current challenges [J].
Rex, JH ;
Pfaller, MA ;
Walsh, TJ ;
Chaturvedi, V ;
Espinel-Ingroff, A ;
Ghannoum, MA ;
Gosey, LL ;
Odds, FC ;
Rinaldi, MG ;
Sheehan, DJ ;
Warnock, DW .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :643-658
[6]   Practice guidelines for the management of cryptococcal disease [J].
Saag, MS ;
Graybill, RJ ;
Larsen, RA ;
Pappas, PG ;
Perfect, JR ;
Powderly, WG ;
Sobel, JD ;
Dismukes, WE .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :710-718
[7]  
Scholer H. J., 1980, Antifungal chemotherapy., P35
[8]  
SCHOLER H J, 1970, Mykosen, V13, P179
[9]   IN VITRO STUDIES WITH 5-FLUOROCYTOSINE [J].
SHADOMY, S .
APPLIED MICROBIOLOGY, 1969, 17 (06) :871-&
[10]  
Viviani MA, 1997, J MED VET MYCOL, V35, P355